Antibodies in Influenza Vaccine and Therapeutic Design
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Influenza Virus Vaccines".
Deadline for manuscript submissions: closed (10 June 2021) | Viewed by 6555
Special Issue Editor
Interests: Antibodies; Influenza virus; Natural Killer (NK) cells; Fc-mediated effector functions; Antibody-dependent cellular cytotoxicity (ADCC)
Special Issue Information
Dear Colleagues,
A universal influenza vaccine that provides broad protection has eluded influenza virus researchers for decades. The effectiveness of current influenza vaccines is limited by antigenic drift, antigenic shift and suboptimal responses in high-risk groups. To overcome these issues, there has been a renewed interest in developing influenza vaccines that induce broadly-reactive antibodies targeting conserved regions of the influenza virus (such as the hemagglutinin stem). Cross-reactive influenza antibodies can bind across many different strains and subtypes of influenza virus and are capable of providing protection through the neutralisation of free virus as well as through Fc-mediated effector functions inclyding antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP). Passive infusions of monoclonal or polyclonal antibodies have also demonstrated promising results as a potential therapeutic intervention for severe influenza infections. As such, antibodies are central to the development of more universal influenza vaccines and novel anti-viral therapies. In this Special Issue, we invite you to submit research articles and reviews on a range of research topics relating to the role of Antibodies in Influenza Vaccine and Therapeutic Design.
Dr. Hillary Anne Vanderven
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Antibodies
- Influenza virus
- Vaccines
- Antibody-based Therapies
- B-cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
